James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Valeant Pharmaceuticals Intl Inc Has Turnaround in Store

VRX stock is still apt to be hot and cold going forward, but it's a "more hot than cold" scenario that suggests Valeant Pharmaceuticals has better days ahead.

Why Investors Shouldn’t Step Into Square Inc Stock Just Yet

Square has a bright future, but SQ stock is disconnected with the company's fundamental reality. Respect the chart rather than the headlines.

Why You Should Keep J C Penney Company Inc on Your Watchlist

JCP stock isn't a must-have name right now, but J C Penney is working and thinking its way back to a growth track.

Why a Growing Side Business Isn’t a Small-Time Endeavor for BP plc (ADR) Stock

BP's growing side business isn't a reason to own BP stock in and of itself, but it should be on current and potential shareholders' minds.

Why I’m Finally Turning Bullish on Twitter Inc Stock

Twitter Inc still has a ton of work to do to make waves for rival Facebook, but TWTR stock will be rewarded just because Dorsey is fighting the good fight.